Overview

Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess antitumor activity of the combination of bevacizumab, pemetrexed and carboplatin, in terms of time to progression.
Phase:
Phase 2
Details
Lead Sponsor:
Armando Santoro, MD
Treatments:
Bevacizumab
Carboplatin
Pemetrexed